Angion Biomedica Corp. (ANGN)

$0.9

+0.04 (+5.03%)
Rating:
Recommendation:
-
Symbol ANGN
Price $0.9
Beta 0.000
Volume Avg. 0.06M
Market Cap 27.102M
Shares () -
52 Week Range 0.78-3.92
1y Target Est -
DCF Unlevered ANGN DCF ->
DCF Levered ANGN LDCF ->
ROE -27.03% Sell
ROA -28.50% Sell
Operating Margin -
Debt / Equity 22.12% Neutral
P/E -0.84
P/B 0.54 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ANGN news


Healthcare
Biotechnology
NASDAQ Global Select

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.